Email Facebook Twitter

Member Info for bigbob0228

Send a private message to bigbob0228

Member Since: Mon, 7th Apr 2008

Number of Share Chat Posts (all time): 117
Number of Share Chat Posts (last 30 days): 0

Last Posted: 8 Oct '15

21 Mar '10

GW pharma (GWP) - An exceptional week for GWP as the company announced that all aspects of safety, quality and efficacy had been resolved for the UK/Spanish licence applications for multiple sclerosis drug, Sativex. The stock moved up from around 100p to finish the week at 121p. Though tempting to take profits, there is significant news flow yet to come from the company. A milestone payment from Bayer Schering of £10 million will be triggered on the UK licence approval in May. A further milestone payment of £2.5 million will be due from Almirall (GW's European partner) on Spanish approval, due Q3 (£8 million was paid in 2009). Results from the clinical study in cancer pain have been confirmed for Spring 2010. It is likely that global distribution deals for Asia and Latam will be announced at the interims in May.

The regulatory announcement this week is a ground breaking event for GW pharma. Sativex approval in Europe is now assured. Given the company was founded in 1998 to develop Sativex, the end of a 12 year road is now in sight. Although reimbursement issues are yet to be resolved, the strength of the commercialisation partners (Bayer Schering and Almirall), will no doubt ensure that any issues are resolved
2 Mar '10

if we can break through 107pps resistance level, next stop should be 128pps.
coments please
13 Nov '09

Could be if anyone out there wants to sell there RBS stake and invest in GWP
10 Nov '09

Check out GWP new website very professional.
19 Oct '09

To apply for a position please send your CV together with a covering letter or email stating your salary expectations to the person indicated. For all recruitment enquiries please contact Crissy Clark on 01980 557009, or e-mail

Clinical Trial Supplies Manager

Full- Time Position

GW Pharma Ltd is the leading company in its field of research and development of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications. Our lead product, Sativex Oromucosal Spray, is licensed in Canada and is currently under review by the MHRA for a UK and Spanish marketing authorisation.

As part of the ongoing expansion of the company’s operations a vacancy has arisen for a person with pharmaceutical experience to lead our Clinical Trial Supplies department.

In this responsible position you will be required to manage drug supplies for worldwide clinical studies of our novel medicines. The scope of this role ranges from protocol interpretation for drug supplies, through label design and approval, labelling and packing and then distribution to sites and depots worldwide.

GW is current planning further phase 3 trials of its lead medicine and has a pipeline of compounds at various stages of their development which will soon be entering early phase trials.

The position would be suitable for someone who is a quick to learn, pays attention to the detail and has the ability to work under pressure with minimal supervisi
13 Oct '09

Lets see if it can be pushed through 104 resistance levels
13 Oct '09

Big buyers moving in 30000@93p

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.